Pharma Catches a Break: Alzheimer's Drug Development Gets Rare Congressional Boost
This article was originally published in RPM Report
Executive Summary
Wyeth has been working hard to generate support for Alzheimer's drug development and easing FDA approval standards. One sign of success: a call to Capitol Hill for a friendly hearing.